Overview


According to FutureWise analysis the market for u.s. topical pain relief in 2023 is US$ 3.03 billion, and is expected to reach US$ 4.12 billion by 2031 at a CAGR of 3.9%.

An application of topical pain relief medications is made directly to the epidermal layer of the skin at the site of inflammation or pain. Topical pain relief products are designed to relieve pain and employ skin as a vehicle for the administration of drugs and exert major effects at the target site
in the central nervous system. Formulations like these contain analgesic or anesthetic agents that are applied to or around the painful area. A slow and gradual release of pain relief medication into the bloodstream is achieved by keeping the blood level relatively constant over time. It is less likely that these medications will cause side effects than oral medications. It is possible to administer both non-opioids and opioids as topical pain relievers. A non-opioid drug includes a nonsteroidal anti-inflammatory drug (NSAIDS), methyl salicylates, capsaicin, lidocaine, etc. Drugs that are considered opioids include buprenorphine and fentanyl. U.S. topical pain relief market growth is primarily driven by osteoarthritis and other bone-related conditions, including diabetic neuropathy, causing pain. U.S. topical pain relief market growth is also boosted by the adoption of topical pain relief products, which cause fewer side effects than oral pain relief, and an increase in the number of geriatrics across the country. Nevertheless, topical pain relievers can cause skin irritation and have a strong smell that hampers market growth. A lucrative growth opportunity for the market is expected to be offered by the development of the online platform for topical therapeutics.

Topical pain relievers are a good alternative for those unable to take oral medications. Topical pain relievers include the drug administrations of capsaicin, tricyclic antidepressants, ketamine, opioids, clonidine, NSAIDs, local anaesthetics and cannabinoids. These medications are available in the form of foams, roll-ons. creams, gels, sprays, patches and sticks.

Basis the distribution channel, the U.S topical pain relief market is fragmented into e-commerce, pharmacies and drug stores and retail and grocery stores. Pharmacies and drug stores accounted for the largest U.S topical pain relief market share due to wide availability and higher presence of drugs. On the contrary, the e-commerce segment is predicted to exhibit significant U.S. topical pain relief market growth over the forecast period due to higher literacy digital-wise amongst the population. Furthermore, these pharmacies offer many advantages like more convenience, easy access to patient reviews, fewer expenses and price comparisons, which drive the segment’s market growth.

  • Johnson and Johnson
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Pfizer Inc.
  • Reckitt Benckiser Group Plc.
  • Sanofi S.A.
  • Topical BioMedics, Inc.
  • AdvaCare Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Nestle S.A.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Therapeutic Class

  • Non-opioids
    • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Methyl Salicylate
    • Capsaicin
    • Lidocaine
    • Other Non-opioids
  • Opioids
    • Buprenorphine
    • Fentanyl

By Type

  • Prescription Pain Relief
  • Over-the-counter (OTC) Pain Relief

By Formulation

  • Cream
  • Gel
  • Spray
  • Patch
  • Others

By Distribution Channel

  • Pharmacies and Drug Stores
  • E-commerce
  • Retail and Grocery Stores
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the U.S Topical Pain Relief Market By Therapeutic Class, By Type, By Formulation and By Distribution Channel
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— U.S.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  U.S. Topical Pain Relief Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of U.S. Topical Pain Relief Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  U.S. Topical Pain Relief Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  U.S. Topical Pain Relief Market, By Therapeutic Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Non-opioids
         1.1. Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
         1.2.Methyl salicylate
         1.3. Capsaicin
         1.4. Lidocaine
         1.5. Other Non-opioids
        2. Opioids
         2.1. Buprenorphine
         2.2. Fentanyl

  • 8.  U.S. Topical Pain Relief Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Prescription Pain Relief
        2. Over-the-counter (OTC) Pain Relief

  • 9.  U.S. Topical Pain Relief Market, By Formulation Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cream
        2. Gel
        3. Spray
        4. Patch
        5. Others

  • 10.  U.S. Topical Pain Relief Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmacies and Drug Stores
        2. E-commerce
        3. Retail and Grocery Stores

  • 11.  Market Share Analysis and Competitive Landscape
    •   1. U.S. Landscape - Key Players, Revenue and Presence
        2. U.S. Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. U.S. Emerging Companies
        4. U.S. - Market Share Analysis and Key Regional Players
        5. U.S. Key Player - Growth Matrix

  • 12.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Johnson and Johnson
                1.1. Company Overview
                1.2. Product Portfolio
                1.3. SWOT Analysis
                1.4. Financial Overview
                1.5. Strategic Overview
        2. Novartis AG.
                2.1. Company Overview
                2.2. Product Portfolio
                2.3. SWOT Analysis
                2.4. Financial Overview
                2.5. Strategic Overview
        3. GlaxoSmithKline Plc.
                3.1. Company Overview
                3.2. Product Portfolio
                3.3. SWOT Analysis
                3.4. Financial Overview
                3.5. Strategic Overview
        4. Pfizer Inc.
                4.1. Company Overview
                4.2. Product Portfolio
                4.3. SWOT Analysis
                4.4. Financial Overview
                4.5. Strategic Overview
        5. Reckitt Benckiser Group Plc.
                5.1. Company Overview
                5.2. Product Portfolio
                5.3. SWOT Analysis
                5.4. Financial Overview
                5.5. Strategic Overview
        6. Sanofi S.A.
                6.1. Company Overview
                6.2. Product Portfolio
                6.3. SWOT Analysis
                6.4. Financial Overview
                6.5. Strategic Overview
        7. Topical BioMedics, Inc.
                7.1. Company Overview
                7.2. Product Portfolio
                7.3. SWOT Analysis
                7.4. Financial Overview
                7.5. Strategic Overview
        8. AdvaCare Pharma
                8.1. Company Overview
                8.2. Product Portfolio
                8.3. SWOT Analysis
                8.4. Financial Overview
                8.5. Strategic Overview
        9. Sun Pharmaceutical Industries Ltd.
                9.1. Company Overview
                9.2. Product Portfolio
                9.3. SWOT Analysis
                9.4. Financial Overview
                9.5. Strategic Overview
        10. Nestle S.A.         
                10.1. Company Overview
                10.2. Product Portfolio
                10.3. SWOT Analysis
                10.4. Financial Overview
                10.5. Strategic Overview

  • 13.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 14.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients